In the current study we investigated the efficacy of the small molecule EGFR inhibitor AG1478 for treatment of CRC using two mouse models, each on a distinct inbred strain and a common F1 genetic background to model genetic heterogeneity of the CRC patient population. This evidence concerns the gene EGFR and colorectal carcinoma.